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Background: Osteopontin (OPN) is a secreted phosphoprotein expressed by neoplastic cells involved in the malignant
potential and aggressive phenotypes of human malignancies, including gastrointestinal stromal tumors (GISTs). Our
previous study showed that OPN can promote tumor cell proliferation in GISTs. In this series, we further aim to
investigate the effect of OPN on apoptosis in GISTs.
Methods: The expression of apoptotic and anti-apoptotic proteins in response to OPN was evaluated. In vitro effects of
OPN against apoptosis in GIST were also assessed. GIST specimens were also used for analyzing protein expression of
specific apoptosis-related molecules and their clinicopathologic significance.
Results: Up-regulation of β-catenin and anti-apoptotic proteins Mcl-1 with concomitant suppression of apoptotic
proteins in response to OPN was noted. A significant anti-apoptotic effect of OPN on imatinib-induced apoptosis
was identified. Furthermore, Mcl-1 overexpression was significantly associated with OPN and β-catenin expression
in tumor tissues, as well as worse survival clinically.
Conclusions: Our study identifies anti-apoptotic effects of OPN that, through β-catenin-mediated Mcl-1 up-regulation,
significantly antagonized imatinib-induced apoptosis in GISTs. These results provide a potential rationale for therapeutic
strategies targeting both OPN and Mcl-1 of the same anti-apoptotic signaling pathway, which may account for resistance
to imatinib in GISTs.
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Gastrointestinal stromal tumors (GISTs), the most com-
mon type of gastrointestinal tract mesenchymal tumor,
originate from the interstitial cells of Cajal in the my-
enteric plexus of the digestive tract, with the stomach
being the most common tumor location. The pathogen-
esis of GIST is gain-of-function mutations of the proto-
oncogene KIT in the majority, or platelet-derived growth
factor receptor α (PDGFRA), with resultant encoding of
related proteins, KIT, or PDGFRA receptors that contain
ligand-independent kinase activity, leading to persistent
and uncontrolled cell proliferation as well as resistance* Correspondence: ysshan@mail.ncku.edu.tw
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unless otherwise stated.to apoptosis [1,2]. It has also recently been proposed
that ETV1, one of the ETS family transcription factors,
cooperates with KIT in the tumorigenesis of GIST [3].
Surgery remains the standard and curative treatment
of choice for patients with a resectable GIST. Target
therapy using imatinib mesylate, a KIT receptor inhibi-
tor, is indicated in those with advanced or unresectable
GIST, or in high-risk patients after surgery as an adju-
vant therapy [4,5]. However, acquired or secondary re-
sistance to imatinib may occur in GIST patients under
imatinib treatment for disease recurrence or progression
[6,7]. It is therefore important to identify the mecha-
nisms underlying imatinib-resistance so that therapeutic
interventions can be developed and applied to this par-
ticular GIST patient group.
Osteopontin (OPN), initially termed Eta-1, standing
for early T cell activation gene 1, or spp1, abbreviated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as a secreted protein from transformed mammalian cells
[8,9]. OPN is currently known as a multifunctional se-
creted glycophosphoprotein expressed in many cell and
tissue types and has been found to participate in numer-
ous cellular functions of both physiologic and pathologic
significance [10,11]. OPN, being frequently overexpressed
in miscellaneous tumor cell types, plays important roles in
their malignant potential and aggressiveness, including
tumor growth, invasion, metastasis, survival, angiogenesis,
and tumorigenesis [12-14].
The clinical significance of OPN as a biomarker for
poor prognosis has been reported in many human ma-
lignancies, including GISTs [12,15-18]. In addition to the
clinicopathologic significance of OPN that independently
predicts poor clinical outcomes in GIST, we also identi-
fied that OPN, upon its interaction with CD44, a type I
transmembrane receptor that recognizes OPN as one of its
important ligands, contributes to tumor cell proliferation
in GIST cell lines [9,19]. These data add to evidence sup-
porting the role of OPN as well as its interaction with
CD44 in the functional regulation of cancer cells [17,18].
In addition to increased proliferation, anti-apoptosis or
suppression of apoptosis, is a common strategy tumor
cells use for tumor progression and drug-resistance.
Based on the significance of OPN in the antagonistic
regulation of apoptosis noted in normal cells as well as
in malignant cells [20-24], pharmaceutical inhibition of
OPN as the target for induction of apoptosis has been
proposed in several human malignancies experimentally
and clinically [25,26]. Since tumor cell proliferation and
apoptosis are closely related and usually coexisting hall-
mark features characteristic of cancer cells, including
GIST, and since we have identified the effect of OPN on
promoting tumor proliferation in GIST, we then further
hypothesize that OPN may also play a role in the regula-
tion of apoptosis in GIST. This study therefore aims to
investigate the effects of OPN in relation to apoptosis
and anti-apoptosis in GIST.
Methods
Cell lines and cell culture
GIST cell lines, including imatinib-sensitive GIST882,
and imatinib-resistant GIST48B and GIST62, were
kindly provided by Dr. Chen from the National Health
Research Institute (Tainan, Taiwan) and were maintained
in RPMI media (Invitrogen) with 10% fetal bovine serum
(Sigma) in a humidified atmosphere with 5% CO2 and
95% air at 37°C.
Construction of shRNA and transient transfection
The shRNA against OPN was conducted by delivery of
shRNA plasmid DNA into cells using the lipofectamine
method with a ratio of 5 μg DNA per 30 μL lipofectamine(Qiagen, Hilden, Germany). Cells transfected with plasmid
of luciferase gene serve as the vector control. After DNA
transfection, cells are grown in regular medium for
48 hours and transfection efficacy is evaluated by lu-
ciferase bioactivity.
Patients and tissue samples
Between January 2002 and January 2012, 31 patients
undergoing surgery for primary GIST at the National
Cheng Kung University Hospital were included for evalu-
ation. The diagnosis of GIST was confirmed by positive
KIT immunohistochemical staining of tumor specimens.
The surgical principle for each patient was to achieve
complete tumor excision with microscopically negative
margins. Patients received regular follow-up at the out-
patient department for abdominal ultrasonography or
CT every three months. No patients received adjuvant or
neoadjuvant therapy. Written informed consent was ob-
tained from all patients and the institute review board of
the National Cheng Kung University Hospital approved
this study.
Western blotting analysis
GIST cell lines GIST882, GIST48B, and GIST62 as well
as tumor tissues preserved in liquid nitrogen (−80°C)
from 31 GIST patients were used for western blotting
analysis. Pair-matched normal tissues from 16 of these
31 patients were also used for comparison. Tumor speci-
mens were lysed with PBS/TDS lysis buffer as described
previously [17,18]. The tissue lysate was centrifuged at
15,000 × g for removal of insoluble cellular materials
(Beckman Coulter). Protein concentrations were mea-
sured by the Pierce BCA protein assay (Pierce). Equal
amounts of protein were subjected to electrophoresis on
10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis gels (Amersham Pharmacia Biotech) and then
transferred to PVDF filters (Perkin-Elmer). GIST882 cell
lysate samples of 30 μg were used for the same proce-
dures. The filters were then blocked in PBS containing
10% skim milk (BD) for 60 minutes and subsequently in-
cubated with a 1:500 dilution of rabbit polyclonal anti-
CD44 antibody (Abcam; ab65829), a 1:50 dilution of
mouse monoclonal anti-β-catenin antibody (Santa Cruz;
sc7963), a 1:1,000 dilution of rabbit polyclonal anti-Mcl-1
antibody (Santa Cruz; sc-819), rabbit monoclonal anti-
Bak antibody (Abcam; ab32371), rabbit polyclonal anti-
XIAP antibody (Abcam; ab2541), and a 1:10,000 dilu-
tion of mouse monoclonal anti-β-actin antibody (Sigma;
A1978) in PBS containing 0.03% Tween 20 overnight. The
PDVF filters were then washed three times for 5 minutes
with PBS containing 0.3% Tween 20 (Merck) and then
incubated for 60 minutes with horseradish peroxidase-
conjugated anti-rabbit IgG antibody (Amersham) for
anti-CD44cyto antibody, anti-Mcl-1 antibody, anti-Bak
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peroxidase-conjugated anti-mouse IgG (GE) for anti-
β-catenin antibody and anti-β-actin antibody. Detection
of secondary antibodies was done by using an enhanced
chemiluminescence system (Amersham). We used the
muscle tissue of the paired-match normal tissue as the
normal control of beta-catenin in Western blot analysis.
The positive control of the western blot analysis of Mcl-1
in GIST was the HEK293 cell lysate.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
Equal amounts of GIST882 cells were deposited on glass
slides for fixation. TUNEL was performed using TACS-2
TdT-Fluor In Situ Apoptosis Detection Kit (Trevigen)
according to the manufacturer’s instructions. The apop-
totic index (per × 200 microscopic field) was calculated
as the number of apoptotic cells × 200 per total number
of cells under a fluorescence microscope (Olympus,
Tokyo, Japan).
Immunohistochemistry
Formalin-fixed and paraffin-embedded blocks from 31
GIST tumor specimens were prepared and treated as
previously described [27]. The same protocol was used
for detection of immunoreactivity, counterstaining, and
selection of positive and negative controls. The primary
antibodies used were mouse monoclonal anti-OPN anti-
body (Santa Cruz; sc21742) at 1:500 dilution and rabbit
polyclonal anti-Mcl-1 antibody (Santa Cruz; sc-819) at
1:1,000 dilution. The secondary antibodies and avidin-
biotin-complex were then applied. Semiquantitative
evaluation of the immunohistochemical staining was
done by two investigators blinded to the clinical infor-
mation separately. The grading of OPN expression was
categorized according to the same criteria as described
previously [18].
Statistical analysis
Comparison between the two groups was done by inde-
pendent sample t-test for continuous variables and χ2
test was employed for analysis of categorical variables.
Significant variables in the univariate analysis were sub-
jected to a multivariate logistic regression for deter-
mination of the independent significance of specific
parameters. One-way ANOVA was used for comparisons
of the means of more than two groups. Correlations be-
tween continuous variables were analyzed by Pearson’s
correlation coefficients. Survival curves were measured
by the Kaplan-Meier method. Disease-specific survival
was defined as the survival period between the diagnosis
of the disease and the death of the patient due to disease
recurrence after surgery. Log-rank test was used for com-
parison of survival between groups. Statistical analyseswere performed using the SPSS computer statistical soft-
ware (SPSS software; version 13.0; Chicago, IL, USA).
A P value of <0.05 was considered significant in each
analysis.
Results
Expression of apoptotic and anti-apoptotic proteins in
response to OPN in GIST cell lines
To assess the in vitro expression of apoptotic and anti-
apoptotic proteins in GIST, we treated the GIST882,
sensitive to imatinib, and imatinib-resistant GIST48B
and GIST62 GIST cell lines with OPN at different con-
centrations and analyzed the protein expression of spe-
cific apoptosis-related proteins by western blotting. In
the anti-apoptotic proteins analyzed, we found increased
expression of Mcl-1 and XIAP with correspondingly
decreased expression of the apoptotic protein Bak, in
response to OPN administration dose-dependently in
GIST882. Knockdown of OPN in GIST882 cell lines
showed inhibition of the anti-apoptotic effects of OPN
demonstrated above (Figure 1). These data suggest a po-
tential in vitro anti-apoptotic effect of OPN via up-
regulation of anti-apoptotic proteins in GIST882. Similar
effects of OPN in promoting the expression of β-catenin
and Mcl-1 were also noted in imatinib-resistant GIST48B
and GIST62. In our previous studies, we identified that
OPN may interact with CD44 to induce CD44 cleavage,
possibly through increased expression of both β-catenin
and cyclin D1 in GIST tumor tissues [17]. Western blot-
ting using GIST882, GIST48B, and GIST62 cell lines
in this study demonstrated compatible results. Dose-
dependent induction of CD44 cleavage and β-catenin
expression in GIST cell lines upon OPN administration
was observed regardless of drug-resistance (Figure 1).
In vitro anti-apoptotic effects of OPN on imatinib-induced
apoptosis in GIST
Imatinib is an inhibitor of both normal and mutated
KIT found in most GISTs and has been used for the
treatment of patients with advanced GIST or for adju-
vant therapy after surgical resection [4,5]. Imatinib has
also been widely used to induce apoptosis in GIST882.
We therefore used imatinib to further evaluate the anti-
apoptotic effects of OPN in GIST882, the known imatinib-
sensitive GIST cell line [28]. In the TUNEL assay for
apoptosis analysis, GIST882 exhibited significant tumor
cell apoptosis upon imatinib treatment in the absence of
OPN, as expected. However, this pro-apoptotic effect of
imatinib on GIST882 was significantly inhibited, or an-
tagonized, upon OPN administration (Figure 2A,B), indi-
cating an in vitro anti-apoptotic effect of OPN in GIST.
We also analyzed the expression of apoptotic and anti-
apoptotic proteins by western blotting in the three groups
of GIST882 cell lines used in the TUNEL assay and
Figure 1 (See legend on next page.)
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Figure 1 Assessment of the activities of anti-apoptotic and apoptotic proteins in response to OPN in GIST. (A) Western blotting analysis
of the total protein extracts from GIST882, GIST48B, and GIST62 cell lysates. Knockdown assessment of OPN by siRNA in GIST882 cell line was also
demonstrated in the lower panel. (B) Quantitation of the western blots by using β-actin as the control, demonstrating increased activities of
the anti-apoptotic proteins, Mcl-1 and XIAP, with concomitant suppressed activities of apoptotic proteins Bak, after OPN administration in a
dose-dependent manner in imatinib-sensitive GIST882. There were also increased activities of CD44 cleavage and β-catenin (upper). Similar
effects of OPN in promoting the expression of β-catenin and Mcl-1 were also noted in imatinib-resistant GIST48B and GIST62 (Columns, mean of
results in triplicate; bars, SD. *, P <0.05).
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of β-catenin, Mcl-1, and XIAP were compatible with
and corresponding to the results from the TUNEL assay
(Figure 2C,D). Similarly, in imatinib-resistant GIST cell
lines GIST48B and GIST62, significant upregulation of
β-catenin and anti-apoptotic protein Mcl-1 in response
to OPN was noted (Figure 3). Taken together, these find-
ings suggest a significant anti-apoptotic effect of OPN
against imatinib-induced apoptosis in GIST.
In conclusion, we suggest that OPN contributes to sig-
nificant anti-apoptotic effects in GIST, against imatinib-
related apoptosis specifically, through the mechanism
of up-regulation of β-catenin and anti-apoptotic pro-
tein Mcl-1, with concomitant suppression of apoptotic
proteins.
Significant correlation of β-catenin and anti-apoptotic
protein Mcl-1 expression in GIST
In our previous investigations of the interaction of OPN
and CD44 and the associated clinicopathologic signifi-
cances in GIST, β-catenin was found likely to play an
important role in the regulation of downstream signaling
and functional effects subsequent to OPN and CD44
interaction [17]. In accordance with other series sug-
gesting that OPN may be related to the induction of
β-catenin or Wnt signaling pathways for regulating
tumor progression, including resistance to apoptosis, in
cancer cell lines [26,29-31], we confirmed that β-catenin
can be a downstream effecter of OPN in GIST and may
be regulating the expression of anti-apoptotic protein
Mcl-1 (Figures 1–3). To further evaluate the association
of β-catenin and Mcl-1, we analyzed the expression of
both proteins in 31 patients with GIST by western blot-
ting in the tumor specimens and normal counterpart tis-
sues (Figure 4A). Having been normalized to β-actin for
quantification of protein expression, both β-catenin and
Mcl-1 exhibited tumor-specific overexpression, with sig-
nificantly increased level of expression in tumor tissues
relative to normal tissues (P <0.001). The average protein
expression levels of β-catenin and Mcl-1 were 0.42 ± 0.25
and 0.80 ± 0.21 (mean ± SD), respectively (Figure 4B).
Additionally, we also analyzed the correlation between
the expression levels of β-catenin and Mcl-1 and found
that these two proteins showed significant positive corre-
lations (Figure 4C). These results further support theclose association between β-catenin and Mcl-1, as well as
the significant regulatory role of β-catenin in GIST, as
demonstrated in the western blotting analysis in GIST
cell lines (Figures 1–3).
Clinicopathologic significance of Mcl-1 expression in GIST
In GIST tumor specimens, increased expression of OPN
and Mcl-1 can also be observed by immunohistochemi-
cal staining (Figure 4D). The expression and grading of
OPN in GIST has been previously described [17]. To
further evaluate the clinicopathologic significance of
Mcl-1 expression in GIST, we use the mean tumor
Mcl-1 expression value of 0.8 by western blotting as the
cut-off level to define Mcl-1 activity in patients with
GIST. Patients with Mcl-1 levels ≥0.8 were those with
strong Mcl-1 expression and others were those with weak
Mcl-1 expression. Table 1 demonstrated the demograph-
ics and clinicopathological data in 31 patients with GIST
with strong or weak Mcl-1 expression. No difference
existed between the two groups in terms of age, gender,
symptoms and signs, tumor size, mitotic figures, and
recurrence. However, patients with strong Mcl-1 ex-
pression were significantly associated with a higher pro-
portion of tumor localization at the stomach (P = 0.020)
and strong OPN expression (P = 0.007). Subsequent multi-
variate analysis of these parameters revealed that only
strong OPN expression remained the independent factor
associated with increased Mcl-1 expression, indicating a
significant and close correlation between OPN and Mcl-1
in GIST. These clinicopathologic data may also partly pro-
vide additional support to our previous in vitro findings
that OPN contributes to significant anti-apoptotic effects
in GIST through up-regulation of the anti-apoptotic pro-
tein Mcl-1. In the Kaplan-Meier estimation for overall and
disease-specific survivals, patients with strong Mcl-1 ex-
pression showed worse overall and disease-specific sur-
vivals, compared with those with weak Mcl-1 expression
(P = 0.045 and 0.042, respectively) (Figure 5). These results
revealed a prognostic value of Mcl-1 expression in patients
with GIST.
Discussion
The anti-apoptotic role of OPN has been described in
several human malignancies, including hepatocellular
carcinoma (HCC), colorectal cancer, pancreatic cancer,
Figure 2 (See legend on next page.)
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Figure 2 Antagonistic effect of OPN on imatinib-induced apoptosis in GIST882 by TUNEL assay. (A) Representative images indicating
changes in the number of TUNEL-positive GIST882 tumor cells treated with imatinib (1 μM) with or without OPN administration (2 μg/mL).
(Original magnification: ×200). (B) The number of TUNEL-positive tumor cells increased significantly in GIST882 treated with imatinib, whereas
their numbers decreased significantly with simultaneous administration of OPN upon imatinib treatment, indicating an in vitro anti-apoptotic
effect of OPN in GIST (Columns, mean of results in triplicate; bars, SD. *, P <0.001) . (C) Western blotting analysis of GIST882 cell lines treated
with imatinib and/or OPN, corresponding to the treatment used in the TUNEL assay. (D) Quantification of the western blots indicating that
significant changes in the expression of anti-apoptotic and apoptotic proteins, in response to OPN in GIST882 cell lines treated with imatinib,
were similar to changes in the percentage of apoptotic cells in the TUNEL assay (Columns, mean of results in triplicate; bars, SD. *, P <0.05,
one-way ANOVA).
Figure 3 Upregulation of β-catenin and anti-apoptotic protein
Mcl-1 in response to OPN in GIST cell lines resistant to imatinib.
(A) Western blotting analysis of GIST48B and GIST62 cell lines treated
with imatinib (1 μM) or OPN (2 μg/mL). (B) Quantification of
the western blots showing significant changes in the expression
of β-catenin and anti-apoptotic protein Mcl-1 in relation to OPN
administration in GIST48B and GIST62 (Columns, mean of results in
triplicate; bars, SD. *, P <0.05).
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[22-24]. In this study, we identified the anti-apoptotic
effect of OPN in GIST for the first time. This anti-
apoptotic effect of OPN, through β-catenin-mediated up-
regulation of anti-apoptotic protein Mcl-1, was able to
attenuate imatinib-induced apoptosis in GIST in vitro,
suggesting a possible role of OPN and Mcl-1 in the
mechanism underlying drug resistance to imatinib in
GIST patients. The results from our study were similar
to those of one report in which OPN was found to
up-regulate the anti-apoptotic protein Bcl-2 to cause
inhibition of apoptosis, thus enhancing resistance to
chemotherapy in lung cancer cell lines, indicating the
involvement of OPN in the development of acquired che-
moresistance [16]. One report also proposed that OPN,
being a main anti-apoptotic factor that inhibited caspase
3-dependent apoptosis, was responsible for resistance to
chemotherapy in a murine breast cancer cell line model
[32]. Another study also identified that enhanced multi-
drug resistance in mesothelioma cells was induced and
mediated through the anti-apoptotic effect of OPN [33].
In line with these studies, our finding that OPN exhibited
significant anti-apoptotic effects in GIST, and specifically
in the presence of imatinib, through anti-apoptotic pro-
tein Mcl-1 up-regulation, may be of value in supporting
the rationale for development of new pharmaceutical
strategies against imatinib-resistant GIST, which may be
common in patients with disease recurrence or progres-
sion after imatinib treatment [6,7]. Our previous study
has proved OPN overexpression to be associated with
tumor recurrence in patients with resectable GIST [18].
Further studies are necessary to investigate the role of
OPN expression in the particular GIST patient group
undergoing neoadjuvant or adjuvant imatinib treatment
that subsequently developed drug-resistance.
Some studies have focused on therapeutic agents or
manipulations targeting apoptosis-related molecules in
the treatment of GIST. Pharmaceutical molecules used to
induce or promote apoptosis in GIST include Bortezomib,
a dipeptide boronic acid inhibitor of the 20S proteasome
that, in part, impedes the degradation of pro-apoptotic
Figure 4 Expression and correlation of β-catenin and Mcl-1 in GIST. (A) Representative tumor (T) and normal (N) tissue samples analyzed by
immunoblotting with anti-β-catenin, anti-Mcl-1, and anti-β-actin antibodies. (B) Comparison of the average β-catenin and Mcl-1 protein expression
by western blotting analysis in tumor tissues (mean ± SD, 0.42 ± 0.25 and 0.80 ± 0.21, respectively, n = 31) and normal counterpart tissues
(mean ± SD, 0.03 ± 0.07 and 0.36 ± 0.26, respectively, n = 16). Columns, mean; bar, SD. *, P <0.001. Equal amounts of protein loading were ensured using
β-actin as the internal control. (C) There was a significantly positive correlation between β-catenin and Mcl-1 expression by Pearson correlation analysis
(r = 0.660; P <0.001). (D) Representative immunohistochemical staining showing strong immunoreactivity for OPN (upper) and Mcl-1 (lower) in GIST.
Original magnification, ×200.
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and MegaFaL, a synthetic compound containing a hex-
americ form of soluble forms of Fas ligand (FasL;
CD95L), which binds to Fas receptor for induction of
Fas-mediated apoptosis [34,35]. One series also proposed
that ABT-737, the pro-apoptotic Bcl-2/Bcl-xL inhibitor,
can synergistically promote imatinib-induced cytotoxicity
via apoptosis [36]. Our study suggests that OPN, withits igniting or initiating role of specific anti-apoptotic
signaling transduction via up-regulation of anti-apoptotic
protein Mcl-1 and its significant anti-apoptotic effect
on inhibiting imatinib-induced apoptosis, may be a po-
tential and promising target for pharmaceutical inter-
vention in GIST resistant to conventional imatinib
treatment. Along with our previous findings [17,18], we
identified the biologic significance of OPN in GIST to
Table 1 Demographics and clinicopathological data in patients with GIST according to Mcl-1 expression
Mcl-1 expression






No. of patients (%) No. of patients (%) P value * P value *
Number of patients 15 (48.4) 16 (51.6) 31 (100) – –
Age (years), mean ± SD 57.3 ± 14.4 63.2 ± 11.8 60.4 ± 13.3 0.225 0.505
Sex
Male 7 (46.7) 8 (50) 15 (48.4) 0.853 0.465
Female 8 (53.3) 8 (50) 16 (51.6)
Symptom and signs
Yes 12 (80) 11 (68.7) 23 (74.2) 0.474
No 3 (20) 5 (31.3) 8 (25.8)
Tumor location
Stomach 5 (33.3) 12 (75) 17 (54.8) 0.020 0.051
Intestine 10 (66.7) 4 (25) 14 (45.2)
Tumor size (cm), mean ± SD 8.0 ± 5.2 7.4 ± 4.5 7.7 ± 4.8 0.745
Mitosis (HPF), mean ± SD 20.3 ± 22.9 16.1 ± 31.7 18.1 ± 27.4 0.672
Recurrence
Yes 5 (33.3) 4 (25) 9 (29) 0.609
No 10 (66.7) 12 (75) 22 (71)
Osteopontin expression**
Strong 5 (33.3) 13 (81.3) 18 (58.1) 0.007 0.015
Weak 10 (66.7) 3 (18.7) 13 (41.9)
SD indicates standard deviation; HPF: high-power fields.
*Significant at the level of P <0.05.
**Strong: 3+; Weak: <3 + .
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proliferation-promoting as well as anti-apoptotic effects,
indicating a pivotal role of OPN in tumor progression and
malignant potential in GIST. These also provide evidence
supporting OPN as an important target of pharmaceutical
intervention in the treatment of GIST.
Mcl-1, a member of the anti-apoptotic Bcl-2 family,
was originally cloned as an immediate-early induction
gene expressed during differentiation of the ML-1
myeloid leukemia cells and functions as a regulator
for survival and development in diverse cell types
physiologically. In tumor biology, Mcl-1 plays an onco-
genic role by maintaining tumor cell survival through its
anti-apoptotic function [37,38]. Overexpression of Mcl-1
has been reported in a wide variety of human cancers, in-
cluding gastrointestinal malignancies such as colorectal
cancer, gastric cancer, and HCC [39-41]. Our study is the
first to document Mcl-1 overexpression, its association
with OPN anti-apoptotic effects, and its prognostic sig-
nificance in predicting poor survival in GIST. We also
identified a positive correlation in the expression of
β-catenin and Mcl-1 in both GIST tumor specimens andGIST cell lines, suggesting that β-catenin may be an ef-
fector of OPN-mediated up-regulation of Mcl-1 and
anti-apoptosis in GIST. However, to further verify and
conclude this putative mechanism of OPN-mediated up-
regulation of Mcl-1 through β-catenin in GIST proposed
in our series, subsequent functional studies may be ne-
cessary. A similar regulatory role of OPN in β-catenin
functions for anti-apoptosis has also been proposed in
another study in which OPN was found to promote
β-catenin signaling to induce resistance to apoptosis in
prostate cancer cells [24].
It has been reported that Mcl-1 promotes cell survival
by suppressing cytochrome c release from mitochondria
through neutralization of pro-apoptotic proteins includ-
ing Bak [42]. This is compatible with our finding that in-
creased Mcl-1 expression was coupled with deceased
expression of Bak, which may be part of the signaling
pathway accounting for the anti-apoptotic function of
Mcl-1 in response to OPN in GIST (Figure 1).
Mcl-1 has also been implicated as a key element in the
resistance to conventional cancer therapies in certain
human malignancies, including chronic myeloid leukemia,
Figure 5 Kaplan-Meier survival curves for overall survival (A) and
disease-specific survival (B) in patients with GIST with respect to
Mcl-1 expression. Log-rank test reveals that patients with strong
Mcl-1 expression were significantly associated with worse overall
and disease-specific survivals. The P value of the log-rank test is
also shown.
Hsu et al. World Journal of Surgical Oncology 2014, 12:189 Page 10 of 12
http://www.wjso.com/content/12/1/189HCC, and cholangiocarcinoma [43-46]. The signifi-
cance of Mcl-1 in its association with drug resistance
and its overexpression in these human malignancies
makes Mcl-1 a potential therapeutic target for inter-
vention and treatment. However, though Mcl-1 over-
expression in GIST was related to poor survival in this
study, we have also noted the lack of association of
strong Mcl-1 expression with mitotic rate, tumor
size, and tumor location, three widely recognized and
strongly validated prognostic parameters of GISTs.
As revealed by the title of the study, the major finding ofthis study is the anti-apoptotic effects of OPN through
up-regulation of Mcl-1 in GIST. Mcl-1, being an anti-
apoptotic protein, may be more likely to be an important
mediator and participant in the signal pathways involved
in the anti-apoptotic effects of OPN in GIST, rather than
the different mechanisms regarding tumor proliferation
and progression. It is therefore reasonable that the ex-
pression of the anti-apoptotic protein Mcl-1, is not dir-
ectly associated with mitotic rate and tumor size, two
major reliable indicators and poor prognostic factors for
tumor proliferation, growth, and progression in GIST.
According to our study, OPN, through up-regulation
of anti-apoptotic protein Mcl-1, antagonized imatinib-
induced apoptosis in GIST in vitro, suggesting a potential
role of OPN and Mcl-1 in the mechanism underlying
drug resistance to imatinib in GIST. As a result, Mcl-1 is
more likely to be involved in the anti-apoptosis and drug
resistance in GIST. This potential role of Mcl-1 in GIST
drug-resistance merits further investigations. Our study
also interestingly identified that strong Mcl-1 expression
was associated with the favorable prognostic factor of
gastric location in the univariate analysis, although this
was only of borderline significance in the multivariate
analysis (P = 0.051); the significance of this association is
not clear. However, this is similar to another study in
which CD133, being more significantly and more fre-
quently expressed in gastric GIST (48%) than in intestinal
GIST (4%), was also found to be a significant poor prog-
nostic factor regarding overall survival in GIST [47]. It is
notable that CD133, one of the well-recognized cancer
stem cell markers in the GI tract, may potentially be in-
volved in drug-resistance in GIST. This is also similar
to the proposed role of Mcl-1 in the anti-apoptosis and
drug-resistance in GIST in our study and awaits further
investigation.
In this study, we found a significant association of
OPN and increased Mcl-1 expression (Figure 1 and
Table 1). We thus propose that OPN and Mcl-1 may
be an upstream initiator and downstream effector, re-
spectively, of the same anti-apoptotic signal pathway,
in their contribution to resistance to imatinib-induced
apoptosis in GIST. It is theoretically possible to simultan-
eously inhibit or target these two anti-apoptotic mole-
cules on the same axis of survival signaling in order to
obtain synergistic efficacy for induction of GIST tumor
cell apoptosis. Interestingly, recent studies have identified
that cyclooxygenase-2 inhibitors can induce apoptosis
and anti-tumor activities through down-regulation of
OPN as well as Mcl-1 [29,48,49]. We therefore consider
the use of cyclooxygenase-2 inhibitors for induction of
apoptosis via down-regulation of dual targets of OPN
and Mcl-1 as a promising strategy in the treatment of
GIST, especially in imatinib-resistant GIST; further in vitro
and in vivo studies are undergoing.
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In conclusion, we identified the anti-apoptotic effect
of OPN in GIST for the first time. This anti-apoptotic
effect of OPN, through β-catenin-mediated up-regulation
of anti-apoptotic protein Mcl-1, also antagonized imatinib-
induced apoptosis in GIST in vitro, suggesting a potential
role of OPN and Mcl-1 in the mechanism underlying drug
resistance to imatinib in GIST patients. Our results there-
fore provide evidence supporting the rationale for thera-
peutic strategies targeting both OPN and Mcl-1 to
interrupt associated anti-apoptotic signaling in drug-
resistant GIST for prevention of tumor progression.
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